Why Curis, Inc. Is Soaring Today
Traders cheer after the company reports upbeat regulatory news. Here's what investors need to know.
Curis
CRIS
CRIS
$9.83
-$0.44
-4.3%
Price as of January 26, 2021, 8:27 p.m. EST
View Interactive CRIS Charts
A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.
Interactive Chart
News & Analysis: Curis
Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning
The biopharma reported second-quarter 2017 earnings and data from a key mid-stage trial.
3 Top Stocks Under $5
Cheap stocks are often cheap for a reason, but sometimes the market has mispriced their potential.
FDA Lifts Clinical Hold on Curis Cancer Drug, Shares Surge
The FDA lifts its clinical hold on Curis cancer drug and shares surge on the news.
Today’s Top Biotech Stories: Curis, Amgen, and Novartis
Curis, Amgen, CytRx, and Novartis could make waves in the biotech sector this morning.
This Week in Biotech
A mixed bag of clinical studies, a highly-awaited FDA panel thumbs-up, and an unwelcome subpoena from the Department of Health and Human Services for one biotech company are this week's top stories.
Why Curis Inc. Shares Tanked
Curis shares sink after reporting early-stage clinical data involving CUDC-907. Is now the time to buy, or should shareholders stick to the sidelines?
This Week in Biotech
Two positive clinical studies, a partial clinical hold by the FDA, a scrapped phase 2 study, and an expanded strategic partnership to fight obesity are among this week's top stories in the biotech sector.
Why Curis Inc. Shares Sank Like a Stone
Curis goes down for the count after the Food and Drug Administration halts enrollment in an early-stage cancer study.
Why Myriad, Curis, and VIVUS Could Pop or Drop Today
These four stocks could make big moves today. Let's check in on the headlines moving Myriad, Jazz, Curis, and VIVUS.
